Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Ophthalmol ; 15: 133, 2015 Oct 13.
Article in English | MEDLINE | ID: mdl-26462481

ABSTRACT

BACKGROUND: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in newer therapies. METHODS: An international survey was distributed to dry eye researchers and expert practitioners via an internet survey. The survey data collected were analyzed with descriptive statistics. RESULTS: One hundred and fifteen respondents completed the survey; of these, 66 % were cornea specialists. The most commonly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluorometholone (FML) 0.1 % (59/99, 60 %), loteprednol etabonate 0.5 % (50/99, 51 %), and autologous serum eye drops (ASD; 48/97, 49 %). The most commonly prescribed non-topical medications included essential fatty acid supplements (72/104, 69 %), low-dose doxycycline (oral; 61/100, 61 %), and flaxseed supplements (32/96, 33 %) as well as punctal plugs (76/102, 75 %). Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %), followed by less than 2 weeks (24/86, 28 %) and with topical CSA between 2 to 8 weeks (45/85, 53 %) followed by 2 to 6 months (24/85, 28 %). The top three signs and symptoms reported to indicate treatment response were, in order, fluorescein staining of the cornea, reduction in foreign body sensation, and reduction in burning sensation. CONCLUSION: This survey offers insight into current expert opinion in the treatment of DED. The results of this survey are hypothesis generating and will aid in the design of future clinical studies.


Subject(s)
Keratoconjunctivitis Sicca/therapy , Practice Patterns, Physicians' , Sjogren's Syndrome/therapy , Anti-Allergic Agents/administration & dosage , Aqueous Humor , Cyclosporine/administration & dosage , Doxycycline/administration & dosage , Expert Testimony , Flax , Fluorometholone/administration & dosage , Glucocorticoids/administration & dosage , Health Care Surveys , Humans , Immunosuppressive Agents/administration & dosage , Lacrimal Apparatus/surgery , Loteprednol Etabonate/administration & dosage , Prosthesis Implantation , Serum
2.
J Refract Surg ; 28(8): 589-91, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22869236

ABSTRACT

PURPOSE: To present a case of unilateral hypopyon uveitis that began 15 days after uneventful bilateral LASIK in a 24-year-old man with an undisclosed history of ulcerative colitis. METHODS: Case report. RESULTS: The hypopyon uveitis completely resolved after treatment with aggressive topical and oral steroid agents in combination with topical antibiotic coverage. CONCLUSIONS: Although rare, visually significant hypopyon uveitis may arise after LASIK in the setting of ulcerative colitis and positive human leukocyte antigen (HLA) B27. Early recognition and treatment can result in an excellent outcome. The exact relationship between hypopyon uveitis and LASIK is impossible to ascertain.


Subject(s)
Colitis, Ulcerative/complications , Granuloma/etiology , Keratomileusis, Laser In Situ , Lasers, Excimer/therapeutic use , Postoperative Complications , Uveitis, Anterior/etiology , Administration, Oral , Administration, Topical , Astigmatism/surgery , Colitis, Ulcerative/drug therapy , Fluprednisolone/analogs & derivatives , Fluprednisolone/therapeutic use , Glucocorticoids/therapeutic use , Granuloma/diagnosis , Granuloma/drug therapy , Humans , Male , Myopia/surgery , Prednisone/therapeutic use , Tomography, Optical Coherence , Uveitis, Anterior/diagnosis , Uveitis, Anterior/drug therapy , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...